2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.22 Outcomes of EGFR-mutant squamous cell non-small cell lung cancers with amivantamab plus lazertinib

Pdf Summary

The document presents a study on the efficacy of the drug combination Amivantamab and Lazertinib for treating patients with epidermal growth factor receptor (EGFR)-mutant squamous cell carcinoma (SCC) of the lung. These drugs have been investigated through several clinical trials, including the MARIPOSA, CHRYSALIS-2, and PALOMA-3 trials, aimed at evaluating their performance in both treatment-naïve and treatment-refractory settings.<br /><br /><strong>Study Background and Methodology:</strong><br />EGFR-mutant SCCs have historically shown limited responses to treatment with EGFR tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody, along with Lazertinib, a selective third-generation EGFR TKI, have been approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC). The clinical trials MARIPOSA, CHRYSALIS-2, and PALOMA-3 were utilized to assess their efficacy specifically in EGFR-mutant SCC.<br /><br /><strong>Study Findings:</strong><br />- In the MARIPOSA trial, which included treatment-naïve participants, the objective response rate (ORR) was 67%, with a median progression-free survival (PFS) of 9.2 months and a median duration of response (DoR) of 10.9 months for those with SCC.<br />- For the CHRYSALIS-2 and PALOMA-3 trials involving treatment-refractory cases, the ORR was 40%, with both trials showing the drug combination to be generally effective.<br />- The presence of specific EGFR mutations and other demographic factors also played a role in treatment outcomes.<br /><br /><strong>Conclusion:</strong><br />The pooled analysis indicates that Amivantamab plus Lazertinib represents a promising treatment option for patients with EGFR-mutant SCC, demonstrating meaningful response rates in both treatment-naïve and treatment-refractory settings. These results support the consideration of this drug combination as a viable new treatment option for this patient population.

Asset Subtitle

Regina M. Koch

Keywords

Amivantamab

Lazertinib

EGFR-mutant

squamous cell carcinoma

lung cancer

clinical trials

MARIPOSA trial

CHRYSALIS-2 trial

PALOMA-3 trial

treatment efficacy